Zealand Pharma A/S (OTCPK:ZLDPF) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT
Company Participants
Adam Steensberg – President & CEO
Conference Call Participants
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Presentation
Prakhar Agrawal
Senior Biotech Analyst
All right. Good morning, everyone. Welcome to day 2 of Cantor’s Global Healthcare Conference. My name is Prakhar Agrawal. I’m a biotech analyst at Cantor. And starting today, we are very excited to host the team of Zealand Pharma. And representing Zealand, coming all the way from Europe, we have Adam Steensberg, CEO. Adam, thank you for joining us.
Adam Steensberg
President & CEO
Thanks a lot. Happy to be here.
Question-and-Answer Session
Prakhar Agrawal
Cantor Fitzgerald & Co., Research Division
Obviously, a big year for Zealand and big next 12 months for Zealand. So maybe why don’t we just start off with an overview of where things are and some of the key priorities for the company?
Adam Steensberg
President & CEO
Absolutely. No, as you mentioned, it has been a very big year for us as we are, you can say, pursuing our ambition of becoming one of the key players in the growing obesity market. Really, we kicked off the year with a fantastic collaboration agreement with Roche around our main asset, petrelintide, which I’m sure we’ll get to talk more about. And since then, our focus with Roche has really been to make sure that we can actually accelerate that program together with Roche. And then looking into the next period, we have key data readouts, not only for petrelintide in Phase II, but also with survodutide, which we have licensed to Boehringer in Phase III. So we really are excited about the upcoming period and the news flow that we have approaching rapidly.
#Zealand #Pharma #ZLDPF #Presents #Cantor #Global #Healthcare #Conference #Transcript